Related Experiment Video
Updated: Sep 9, 2025

Functional Near-Infrared Spectroscopy Hyperscanning Study in Psychological Counseling
Published on: January 17, 2025
First Real-World Evidence of an AI-Enhanced Digital Collaborative Care Model to Improve IBS Symptoms
Stephen E Lupe1, Joseph M Olson2, Kendra Kamp3
1The Cleveland Clinic, Cleveland, Ohio, USA.
A novel digital collaborative care model (DCCM) significantly improved irritable bowel syndrome (IBS) symptoms. This approach integrated multidisciplinary care, nutrition, and behavioral therapy, offering sustained relief for IBS patients.
Area of Science:
- Gastroenterology
- Digital Health
- Behavioral Science
Background:
- Health systems face challenges in providing guideline-recommended multidisciplinary care for irritable bowel syndrome (IBS).
- Digital collaborative care models (DCCMs) offer a promising technological solution for enhancing IBS management by integrating experienced providers and digital tools.
Purpose of the Study:
- To evaluate the effectiveness of a novel DCCM in improving clinical outcomes for patients with active IBS symptoms.
- To assess the impact of integrated care pathways, including multidisciplinary teams, personalized nutrition, and brain-gut behavioral therapy, on IBS symptom severity.
Main Methods:
- A prospective, longitudinal, single-arm study assessed the Ayble Health program with 202 participants experiencing active IBS symptoms (IBS-SSS ≥ 75).
- Participants engaged in at least one of three care pathways: multidisciplinary care team, personalized nutrition/elimination diet, or brain-gut behavioral therapy (BGBT).
- AI algorithms supported care personalization by analyzing patient-reported outcomes and identifying key trends.
Main Results:
- A significant average decrease of 140 points in IBS Symptom Severity Scale (IBS-SSS) was observed.
- 86% of participants achieved a clinically meaningful reduction of at least 50 points in IBS-SSS.
- High engagement was noted across pathways, with 98% participating in nutrition, 75% in BGBT, and 77% in the care team; 62% utilized all three.
Conclusions:
- The novel DCCM effectively delivered evidence-based care, leading to clinically significant and sustained symptom relief in patients with active IBS.
- The study highlights the potential of integrated digital care models for managing IBS.
- Further randomized clinical trials are recommended to compare cost-effectiveness and treatment efficacy against standard care.
More Related Videos
Related Concept Videos
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Drugs for Treatment of Constipation-Predominant IBS
Chronic Pancreatitis II: Collaborative Care
Assessment:

